User profiles for Chandramani Singh
 | Chandramani SinghAIIMS, PATNA Verified email at aiimspatna.org Cited by 2252 |
Challenges in haptic communications over the tactile internet
…, J Lugtenburg, K Polachan, PT Venkata, C Singh… - IEEE …, 2017 - ieeexplore.ieee.org
The Tactile Internet presently constitutes a vision of an Internet over which, in addition to
current communications modalities, a sense of touch can be transported. In that case, people …
current communications modalities, a sense of touch can be transported. In that case, people …
Cooperative profit sharing in coalition-based resource allocation in wireless networks
We consider a network in which several service providers offer wireless access to their
respective subscribed customers through potentially multihop routes. If providers cooperate by …
respective subscribed customers through potentially multihop routes. If providers cooperate by …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
…, P Sharma, D Sharma, A Singh, J Singh, P Singh… - The Lancet, 2021 - thelancet.com
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
A game theoretic distributed algorithm for FeICIC optimization in LTE-A HetNets
To obtain good network performance in Long Term Evolution-Advanced (LTE-A) heterogeneous
networks (HetNets), enhanced inter-cell interference coordination (eICIC) and further …
networks (HetNets), enhanced inter-cell interference coordination (eICIC) and further …
[HTML][HTML] Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label …
Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 trial …
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 trial …
[HTML][HTML] Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
[HTML][HTML] Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised …
Background Despite having milder symptoms than adults, children are still susceptible to
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …
